Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atabecestat
- Development stage
- Phase 3
- Lead developer
- Janssen Research & Development
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Atabecestat is an oral, brain-permeable small molecule inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as β-secretase. By inhibiting BACE1, atabecestat reduces the production of amyloid beta (Aβ) peptides from amyloid precursor protein (APP), which are implicated in the pathogenesis of Alzheimer's disease. The drug was developed for the treatment of early-stage Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease. Clinical trials demonstrated that atabecestat significantly reduced Aβ levels in cerebrospinal fluid and plasma, confirming target engagement. However, development was discontinued after reports of liver toxicity and cognitive worsening similar to other BACE inhibitors[1][2][6].
- Brand names
- atabecestat
- Other names
- atabecestat1200493-78-2N-(3-((4S)-2-amino-4-methyl-4H-1,3-thiazin-4-yl)-4-fluorophenyl)-5-cyano- 2-pyridinecarboxamide
02
Targets
BACE1 (Beta-site APP-cleaving enzyme 1)BACE2 (Beta-site amyloid precursor protein cleaving enzyme 2)
Beyond the preview
Go deeper on atabecestat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atabecestat.